| Methods |
1‐week washout; 1‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg at 2 consecutive visits during run‐in, with a difference of 10 mm Hg or less between 2 visits; 6‐week double‐blind treatment |
| Participants |
Benazepril 20 mg: n=42(28 males,14 females); mean age=53.7 years; baseline sitting SBP=153 mm Hg, DBP=104 mm Hg;
Placebo: n=40(22 males,18 females); mean age=53.5 years; baseline sitting SBP=153 mm Hg, DBP=103 mm Hg |
| Interventions |
Benazepril 20 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in peak sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported and SE of change reported, endpoint BP reported; endpoint SD not reported, SD of change calculated from N and SE of change; BP data from Fagan abstract; SD of change data from Figure 1, p. 8; Jadad score=4; funding source= Ciba Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
